Skip to main content
BLFS
NASDAQ Industrial Applications And Services

BioLife Solutions Q2 Revenue Jumps 21% to $28.5M, Adjusted EBITDA Hits $7.4M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$33.93
Mkt Cap
$1.66B
52W Low
$17.86
52W High
$34.34
52W Position info
90% above low
Off High info
1.2% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BLFS sits 90% above its 52-week low of $17.86.

Summary

BioLife Solutions reported Q2 2026 revenue of $28.5M (+21% YoY) and adjusted EBITDA of $7.4M, demonstrating robust growth in its core biopreservation business ahead of its pending acquisition by Repligen.


Key Events · Earnings and Guidance · BLFS

  • Revenue Up 21% to $28.5M

    Q2 2026 total revenue reached $28.5 million, a 21% increase over Q2 2025, driven by the market-leading biopreservation media franchise.

  • Adjusted EBITDA of $7.4M (26% Margin)

    Non-GAAP adjusted EBITDA was $7.4 million, or 26% of revenue, up from $5.6 million in Q2 2025, reflecting improved operating leverage.

  • GAAP Net Income Boosted by $42.4M Tax Benefit

    GAAP net income was $45.1 million, including a non-cash $42.4 million income tax benefit from the release of a valuation allowance; adjusted net income was $4.2 million.

  • Strong Cash Position of $113.1M

    Cash, cash equivalents, and marketable securities totaled $113.1 million as of June 30, 2026, providing ample liquidity ahead of the Repligen acquisition.


Analysis · BLFS · Industrial Applications And Services

BioLife Solutions delivered a strong Q2 with 21% revenue growth and a swing to GAAP profitability, though the $45.1M net income was largely driven by a one-time $42.4M tax benefit. The core business showed solid momentum: adjusted EBITDA of $7.4M (26% margin) and cash of $113M provide ample runway ahead of the Repligen acquisition. The company's biopreservation media dominates with over 70% market share in clinical trials, and 18 approved therapies now use its products. This earnings report reinforces the operational strength that made BioLife an attractive target for Repligen's $1.5B buyout, expected to close in Q4 2026.

At the time of this filing, BLFS was trading at $33.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $34.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLFS - Latest Insights

BLFS
Aug 06, 2026, 4:03 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $33.93
Real-time Price: $33.93 info
Change: $0 (0%) info
Market Cap: $1.66B info
BLFS
Jul 23, 2026, 6:21 PM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $31.02
Real-time Price: $33.93 info
Change: +$2.91 (+9%) info
Market Cap: $1.66B info
BLFS
Jul 22, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $31.00
Real-time Price: $33.93 info
Change: +$2.93 (+9%) info
Market Cap: $1.66B info
BLFS
Jul 22, 2026, 6:57 AM EDT
Source: Reuters
Importance Score:
10
Price at Filing: $29.19
Real-time Price: $33.93 info
Change: +$4.74 (+16%) info
Market Cap: $1.66B info
BLFS
Jun 26, 2026, 6:25 PM EDT
Source: Binance News
Importance Score:
9
Price at Filing: $30.55
Real-time Price: $33.93 info
Change: +$3.38 (+11%) info
Market Cap: $1.66B info